DEVELOPMENT OF A NEW VACCINE AGAINST HIV: VIROSOMES INCORPORATING HIV PROTEINS

Projektinformationen

HIV VIROSOMES

ID Finanzhilfevereinbarung: 12183

Startdatum 1 Januar 2005

Enddatum 31 Dezember 2007

Finanziert unter

• Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006.

Gesamtkosten € 1 835 030,00

EU-Beitrag € 973 930,00

Koordiniert durch

POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH
Austria

Ziel

A safe and effective vaccine is the only way to stop the spread of HIV, especially in developing countries. Despite enormous efforts of numerous groups no convincing protective vaccine against HIV-1 has been generated so far. We suggest an alternative appr oach in HIV vaccine development: to test virus like particles composed of primary HIV proteins or recombinant proteins with native conformation which are incorporated into liposomes of the size of virions and with a lipid composition similar to the virus m embrane. The aim of the project is to develop this concept from the laboratory to proof-of concept studies in non-human primates. We recently established a novel large scale technology for generation of liposomes with desired properties and within this pro ject will adapt this technology to incorporate HIV-1 proteins into liposomes thereby stabilising their native conformation. Resulting virosomes carrying HIV proteins will be utilised as prophylactic and therapeutic vaccine against HIV-1 infection. Since th is vaccine is cheap to produce, stable and might be administered in a needle free format, this approach ideally meets the specific needs of developing countries.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › immunology › immunisation
• natural sciences › biological sciences › microbiology › virology
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › health sciences › infectious diseases › RNA viruses › HIV
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Schlüsselbegriffe

• HIV vaccine

Programm/Programme

• FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006.

Thema/Themen

• LSH-2003-2.3.0-1 - Highly innovative approaches for the development of new interventions for HIV, malaria and tuberculosis

Aufforderung zur Vorschlagseinreichung

FP6-2003-LIFESCIHEALTH-3
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

STREP - Specific Targeted Research Project

Koordinator

POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH

• EU-Beitrag: Keine Daten
• Adresse: Nussdorfer Laende 11 ; VIENNA ; Österreich
• Gesamtkosten: Keine Daten

Beteiligte (3)

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Deutschland

• EU-Beitrag: Keine Daten
• Adresse: Meyerhofstrasse 1 ; HEIDELBERG
• Gesamtkosten: Keine Daten

FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE

Niederlande

• EU-Beitrag: Keine Daten
• Adresse: Lange Kleiweg 139 ; RIJSWIJK
• Gesamtkosten: Keine Daten

UNIVERSITY OF NATURAL RESOURCES AND APPLIED LIFE SCIENCES

Österreich

• EU-Beitrag: Keine Daten
• Adresse: Muthgasse 18B ; VIENNA
• Gesamtkosten: Keine Daten